Galderma reports positive topline study results for Restylane Volyme
Galderma said its study of Restylane Volyme for moderate-to-severe temple hollowing in 162 Chinese patients met its primary endpoint, showing effectiveness and safety versus a no-treatment control.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.